Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma - Wikidata - awgldk - TriplyDB

Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma

Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma

http://www.wikidata.org/entity/Q57820342

about

Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives.Recent trends in the treatment of well-differentiated endocrine carcinoma of the small bowel.Update on pancreatic neuroendocrine tumors.Requiem for the term 'carcinoid tumour' in the gastrointestinal tract?Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial.Somatostatin receptors in gastrointestinal stromal tumors: new prognostic biomarker and potential therapeutic strategy Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT.Safety and efficacy of everolimus in adult patients with neuroendocrine tumors.Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.A rare gastric neuroendocrine carcinoma coexisting with Brunner's gland adenoma: A case report.Antitumor effects of somatostatin analogs in neuroendocrine tumors.Anti-vascular endothelial growth factor antibody single therapy for pancreatic neuroendocrine carcinoma exhibits a marked tumor growth-inhibitory effect.Pancreatic Neuroendocrine Tumors: an Update.Priorities for improving the management of gastroenteropancreatic neuroendocrine tumors.Causes of death and prognostic factors in multiple endocrine neoplasia type 1: a prospective study: comparison of 106 MEN1/Zollinger-Ellison syndrome patients with 1613 literature MEN1 patients with or without pancreatic endocrine tumors.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advances Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives.Octreotide LAR: safety and tolerability issues.Gastrointestinal neuroendocrine tumors.Future perspectives on neuroendocrine tumors.Potential synergies for combined targeted therapy in the treatment of neuroendocrine cancer.Therapy innovation for the treatment of pancreatic neuroendocrine tumors.Treatment options for unresectable neuroendocrine liver metastases.Everolimus and mTOR inhibition in pancreatic neuroendocrine tumors.Neuroendocrine neoplasms of the GI tract: the role of cytotoxic chemotherapy.Neuroendocrine tumors of the gastrointestinal tract and the role of cytotoxic chemotherapy.The Antiproliferative Role of Lanreotide in Controlling Growth of Neuroendocrine Tumors: A Systematic Review.Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours.Medical treatment of gastroenteropancreatic neuroendocrine tumors.Plasma chromogranin A response to octreotide test: prognostic value for clinical outcome in endocrine digestive tumors.Nasopharyngeal carcinoid tumor: successful therapy for a tumor in a unique location.Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms.

P2860

Q28290833-589159E7-8814-482F-AF65-FC3C4E1B62F1 Q30364864-9C7E6AC7-3F35-4D95-B322-8C72AE281AC8 Q33753449-6E10FB45-2B1B-467E-87F8-D0E99BEE4F5E Q33782024-C6B24FC3-2C2B-4011-955A-48E4772BD233 Q34453043-0CF0FE04-D8B4-4096-8832-2994C378D043 Q34770091-1290EB62-BD39-449D-BA6B-6804440D9788 Q34887795-83A5A6F5-5533-4A6A-9615-3790E485BA20 Q34965132-65E7673E-2797-4FE2-AAB8-1440901A57A5 Q34978826-081930F2-0335-4DA4-9D03-BAB206DFE051 Q34992833-DDF0AD36-5ACF-4117-838B-43FC8585699C Q35001777-1F000160-1F43-4A95-AAE8-BD8B9B9ED4E1 Q35550939-652EDB2B-5E1E-4117-B04F-8021A6BC86DC Q35669138-C0F9813C-AE51-4698-9B33-30D0A0207900 Q35760798-2541584E-894E-463F-8794-9BA30C690885 Q35837124-0460B67B-7407-4A45-9F78-70C853025E50 Q35944519-5DAD88FF-3A38-4E00-9CAB-8F6C4686B9DD Q36051476-9AF699D1-434E-4336-88E3-5BEC0374B096 Q36230918-BF5EA9D1-0AB0-4E7D-ADF5-744AC865B89C Q36400062-9F7469AC-6A83-4334-A558-91521676481D Q36882123-BC0056C7-D017-4FCD-8A96-A76E2E154751 Q37056120-48E9B550-C4DD-4351-9D4A-A8DE316998FC Q37125550-B5B7B3BE-4DDD-4CE8-9BB6-DAD7F01BE2B7 Q37483944-8C12F042-5673-4458-B222-3B022A07D48B Q37564373-ACB21EDB-A089-458E-BE0A-43DA63E5A4A0 Q37649647-925EB22F-0D57-4BC1-A757-68E26700DCA1 Q37799954-3662D321-F48C-4A13-B322-1BF3DF562E21 Q37843819-27A1B37E-2E47-4759-8034-6E4C57EB6B84 Q37875054-64092895-0CE9-41FD-967E-9E9190A43C53 Q37988905-E340CF3B-5A00-49D4-A016-157DA183E435 Q38014498-B4ED3E78-05B0-4BF0-9223-8A89FF91E911 Q38035844-0D5CA33E-EBD6-4D0C-8FDF-0C00D5D02044 Q38096476-FE6DDEE9-0A11-43A1-AF63-9ADB3C557177 Q38711101-75719C82-5382-42F9-81DC-5A092865D601 Q38755167-D938ED03-B73E-4A17-9415-48E091C4823E Q39217510-2A6B628B-934C-4EA4-B277-C5D106EE258D Q39254045-87733226-92C6-40A4-9C3A-82F738E4483B Q42469904-E1B28DBD-F390-4B59-B915-3C0773EB590E Q46106273-5822C7C9-32F8-4CD7-9D00-AE49AEDFCBD5 Q47724538-797E06D7-858C-4E87-B505-CD9EB17C85D2

P2860

Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma

http://www.wikidata.org/entity/Q57820342

description

im Dezember 2005 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 19 December 2005

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в грудні 2005

@uk

name

Long-term clinical outcome of ...... pancreatic endocrine carcinoma

@en

Long-term clinical outcome of ...... pancreatic endocrine carcinoma

@nl

type

label

Long-term clinical outcome of ...... pancreatic endocrine carcinoma

@en

Long-term clinical outcome of ...... pancreatic endocrine carcinoma

@nl

prefLabel

Long-term clinical outcome of ...... pancreatic endocrine carcinoma

@en

Long-term clinical outcome of ...... pancreatic endocrine carcinoma

@nl

P1433

Q57820342-BB88AEF7-46AD-445F-A0E2-97DBD6E8C7D9

P1476

Q57820342-72A96742-251E-43B3-93EB-B1806E55418D

P2093

Q57820342-2946C7A7-12FB-4BBD-94C1-AA96453BA4AC

Q57820342-2F4AD4C7-D450-43A0-917A-E6A304B3EA53

Q57820342-54EA757E-EEBC-4EAD-BE24-877621B85D10

Q57820342-59948127-4327-4BD1-9DF4-91E58B7353C9

Q57820342-5F35F834-52A2-4A30-98A1-A049B21F9EFD

Q57820342-68E48863-60DB-4EBD-BA11-8D05676D5546

Q57820342-9CB8C6A3-A53C-42BC-80B8-4E0C16538AF9

Q57820342-CC4CF80D-B762-4668-9DFA-9C34A69E558B

Q57820342-CC7AA7B5-C51F-45BB-8A5E-4728692C29B3

Q57820342-F92A9301-9BAA-4E24-BEAD-B2ABEFF25541

P304

Q57820342-839227E1-5466-4ACE-B87A-37BFFF4B04F9

P31

Q57820342-16916CCF-FF6D-4C12-A7E1-DCDF9F24F785

P356

Q57820342-14AD534F-B00C-4C48-88CD-E6C11323CDC2

P433

Q57820342-27F4E34D-D444-4424-8D27-879F2E072435

P478

Q57820342-449245E4-C0D5-4CCD-8A5D-1428C0F9F24E

P50

Q57820342-05D3A6F8-7DDC-45ED-A371-C6E5D0864414

Q57820342-3D21EE71-8D8A-405F-8E4C-BC676FC73FB2

Q57820342-8988751F-B1BC-4ACC-9870-FD2601102A1D

Q57820342-CF0EB3E4-59A6-4157-9510-50748EFAA523

P577

Q57820342-EAA0AC28-5AF7-4C22-B8A6-1AAD27528F1C

P698

Q57820342-A54034B6-FBEA-4281-9555-6FE69FC98248

P356

P1433

Annals of Oncology

P1476

Long-term clinical outcome of ...... pancreatic endocrine carcinoma

@en

P2093

C Bordi

http://www.w3.org/2001/XMLSchema#string

C L Maini

http://www.w3.org/2001/XMLSchema#string

E Iannicelli

http://www.w3.org/2001/XMLSchema#string

G Delle Fave

http://www.w3.org/2001/XMLSchema#string

M Di Fonzo

http://www.w3.org/2001/XMLSchema#string

M S Cattaruzza

http://www.w3.org/2001/XMLSchema#string

P Pederzoli

http://www.w3.org/2001/XMLSchema#string

R Sciuto

http://www.w3.org/2001/XMLSchema#string

V David

http://www.w3.org/2001/XMLSchema#string

V Ziparo

http://www.w3.org/2001/XMLSchema#string

P304

461-466

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/ANNONC/MDJ113

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

Massimo Falconi

Massimo Milione

Francesco Panzuto

Gabriele Capurso

P577

2005-12-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16364959

http://www.w3.org/2001/XMLSchema#string